Aarti Pharmalabs: Business Overview & Financial Analysis
Aarti Pharmalabs is a leading manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, xanthine derivatives, and Contract Development and Manufacturing Organisation (CDMO) services headquartered in Mumbai, Maharashtra. Demerged from Aarti Industries Limited, the company operates manufacturing plants in Tarapur, Vapi, Dombivli, and Atali across Maharashtra and Gujarat. Serving generic drug makers and global innovator pharmaceutical clients, the enterprise maintains an international presence with dispatches across 60+ countries.
Business Segment Mix of Aarti Pharmalabs (Q1 FY2027)
Aarti Pharmalabs structures its operational turnover across core xanthine derivatives, active pharmaceutical ingredients, and contract manufacturing services.
- Xanthine Derivatives Share – 57.0% of Total Revenue
- APIs & Intermediates Share – 30.0% of Total Revenue
- CDMO Segment Share – 7.0% of Total Revenue
- Allied Products & Services Share – 6.0% of Total Revenue
Xanthine derivatives generate over half of corporate turnover, making the company the world's third-largest producer of xanthine derivatives. Expanding high-margin CDMO services provides revenue diversification across custom synthesis contracts.
Geographic Revenue Breakdown of Aarti Pharmalabs (Q1 FY2027)
The enterprise balances its product dispatches between international export markets and domestic pharmaceutical processors.
- International Export Market Share – 60.0% of Total Revenue
- Domestic Indian Market Share – 40.0% of Total Revenue
- Xanthine Segment Export Share – 79.0% of Xanthine Division Turnover
- Global Export Footprint Scale – Active sales dispatches across 60+ countries
International sales generate six-tenths of total turnover, supported by direct customer relationships across regulated export markets. Exporting 79% of xanthine volume positions the company as a key non-Chinese supplier under global "China+1" sourcing strategies.
Manufacturing Facilities & Capacity Scale of Aarti Pharmalabs (FY2026)
Aarti Pharmalabs manages multi-purpose chemical reaction blocks and manufacturing units across Maharashtra and Gujarat.
- Total Operational Manufacturing Complexes – 6 manufacturing facilities across India
- Primary Plant Locations – Tarapur, Vapi, Dombivli, and Atali
- Regulatory Certifications Held – USFDA, EDQM, EUGMP, and WHO-GMP
- Newly Commissioned Unit – Tarapur Unit 5 multi-purpose API block
- World Capacity Ranking – 3rd largest global producer of xanthine derivatives
Operating six manufacturing plants ensures continuous production of APIs and complex intermediates. Stringent USFDA and EDQM approvals enable direct active ingredient exports to regulated European and American markets.
Latest Quarterly Financial Performance of Aarti Pharmalabs (Q1 FY2027)
Aarti Pharmalabs recorded double-digit top-line turnover growth and net profit expansion during the first quarter of FY2027.
- Consolidated Revenue from Operations – Rs 535.80 crore (+38.7% YoY vs Rs 386.20 crore in Q1 FY2026)
- Consolidated Operating EBITDA – Rs 132.60 crore (+39.3% YoY vs Rs 95.20 crore in Q1 FY2026)
- Consolidated Operating EBITDA Margin – 24.75% (+10 bps YoY vs 24.65%)
- Consolidated Net Profit After Tax (PAT) – Rs 76.14 crore (+65.4% YoY vs Rs 46.00 crore in Q1 FY2026)
- Consolidated Diluted Earnings Per Share (EPS) – Rs 8.39 per share (+65.2% YoY vs Rs 5.08)
First-quarter consolidated operating revenue expanded 38.7% year-on-year to Rs 535.80 crore, supported by record xanthine sales volumes. Consolidated Net Profit After Tax rose 65.4% to Rs 76.14 crore, driven by operating leverage and joint venture profit contributions.
Standalone Annual Financial Performance of Aarti Pharmalabs (FY2026)
The company achieved full-year turnover growth and operational profitability during full financial year FY2026.
- Full Year Consolidated Revenue from Operations – Rs 1,820.50 crore
- Full Year Consolidated Operating EBITDA – Rs 445.80 crore
- Full Year Operating EBITDA Margin – 24.48%
- Full Year Consolidated Net Profit After Tax (PAT) – Rs 235.40 crore
- Return on Capital Employed (ROCE) Realisation – 16.50%
- Return on Equity (ROE) Realisation – 14.20%
Full-year operating turnover crossed Rs 1,820.00 crore in FY2026, while Net Profit After Tax reached Rs 235.40 crore. Maintaining operating EBITDA margins at 24.48% reflects captive raw material integration across active ingredient product lines.
Balance Sheet Structure & Financial Leverage of Aarti Pharmalabs (Q1 FY2027)
Aarti Pharmalabs operates a conservative capital structure characterized by managed borrowing leverage and equity retention.
- Consolidated Net Debt to Equity Ratio – 0.32x (Disciplined leverage profile)
- Total Shareholder Equity Net Worth Base – ~Rs 1,650.00 crore
- Working Capital Conversion Cycle – 75 days
- Credit Rating Profile – Reaffirmed high investment grade rating profile
Operating with a net debt-to-equity ratio of 0.32x provides balance sheet flexibility to execute capital expansion plans. High shareholder equity backing supports continuous investments in CDMO research and development.
Capex Allocation & Capacity Expansion Roadmap of Aarti Pharmalabs (FY2027–FY2028)
The enterprise executes a structured capital outlay plan to construct intermediate blocks, scale CDMO capabilities, and enter peptide manufacturing.
- Approved Atali Block 2 Expansion Capex Outlay – Rs 149.00 crore brownfield capex project
- Atali Block 2 Capacity Scale – 405 Kilolitres (KL) intermediate block capacity
- Atali Block 2 Commercialization Target – Targeted completion in H2 FY2028
- New R&D Technology Initiative – TIDES platform (Peptides & Oligonucleotides synthesis development)
- Targeted CDMO Sales Growth Guidance – Rs 380.00 crore target in FY2027 (+40% to 50% YoY growth)
Board authorization of Rs 149.00 crore for Atali Block 2 adds 405 KL of intermediate synthesis capacity for CDMO clients. R&D outlays into TIDES (peptides and oligonucleotides) prepare the company to offer advanced therapeutic building blocks.
Strategic Outlook & Management Commentary of Aarti Pharmalabs (Q1 FY2027 Concall)
Management guidance outlines strategic growth priorities centered on CDMO revenue scaling, leadership transitions, and long-term earnings targets.
- Management targets achieving a 15.0% to 18.0% annual revenue and EBITDA CAGR over the next 3 to 4 years.
- CDMO segment revenues are projected to grow by 40.0% to 50.0% in FY2027, scaling toward ~Rs 380.00 crore.
- Board elevated Rashesh C. Gogri to Managing Director effective October 1, 2026, to lead corporate strategy.
- Atali Block 2 capex execution will scale intermediate supply for global CDMO partners.
- Xanthine derivative export volumes will be expanded under China+1 supply agreements.
- Capital allocation strategy will prioritize self-funded brownfield additions while preserving a conservative net debt ratio.
Management anticipates strong demand for APIs, intermediates, and CDMO services to support long-term turnover targets. Operational focus centers on commercializing the Atali Block 2 project, expanding peptide R&D capabilities, and maintaining balance sheet health.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Aarti Pharmalabs Stock Exchange Disclosures & Board Meeting Outcomes (August 7, 2026)
- Aarti Pharmalabs Q1 FY2027 Earnings Call Summary & Regulatory Updates (August 8/10, 2026)
- Kotak Neo Q1 FY2027 Financial Performance Summary for Aarti Pharmalabs (August 8, 2026)
- BSE Limited & National Stock Exchange of India (NSE) Filings for Aarti Pharmalabs
- Ticker Finology Aarti Pharmalabs Page
Disclaimer
The information presented above on Aarti Pharmalabs has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Aarti Pharmalabs page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.